SCHEMBL13664182

SCHEMBL13664182

N#Cc1ccc(-n2nc(C(=O)c3ccc(Cl)cc3)c(C#N)c2N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAPK14 Q16539 1/20 0.48
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ABCB1 P08183 1/20 0.44
ADORA1 P30542 1/20 0.44
LMNA P02545 5/20 0.42
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
NLRP3 Q96P20 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CNR1 P21554 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664223 0.92 MAPT (0.52) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664224 0.91 MAPT (0.51) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664161 0.89 MAPT (0.51) MAPTSMN1; SMN2MEN1KMT2APOLB
SCHEMBL13664179 0.89 MAPT (0.50) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664177 0.89 MAPT (0.50) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664168 0.89 MAPT (0.50) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664174 0.89 MAPT (0.52) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13667899 0.89 MAPK14 (0.49) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664163 0.88 MAPT (0.51) MAPTSMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL13664175 0.88 MAPK14 (0.63) MAPTMEN1KMT2AMAPK14GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885SMN1; SMN2 3698/4885MEN1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.